SK 08
Alternative Names: SK-08Latest Information Update: 19 Jun 2025
At a glance
- Originator Zhiyi Biotechnology
- Class Anti-inflammatories; Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Irritable bowel syndrome
- Phase II Inflammatory bowel diseases
- Phase I/II Solid tumours
- Phase I Ulcerative colitis
Most Recent Events
- 09 Mar 2025 Consun Pharmaceutical initiates a phase I trial (In volunteers) in China (PO) (NCT07021157)
- 09 Dec 2024 Guangzhou Zhiyi Biotechnology plans a phase II trial for Uncelrative colitis (Treatment experienced) in July 2025 (NCT06725017)
- 16 Mar 2024 Phase-III clinical trials in Irritable bowel syndrome in China (PO) (NCT06247046)